| Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard-and high-risk myeloma I Goicoechea, N Puig, MT Cedena, L Burgos, L Cordón, MB Vidriales, ... Blood, The Journal of the American Society of Hematology 137 (1), 49-60, 2021 | 97 | 2021 |
| Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) L Sanoja-Flores, J Flores-Montero, JJ Garcés, B Paiva, N Puig, ... Blood cancer journal 8 (12), 117, 2018 | 94 | 2018 |
| Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma JJ Garcés, MT Cedena, N Puig, L Burgos, JJ Perez, L Cordon, ... Journal of Clinical Oncology 40 (27), 3151-3161, 2022 | 50 | 2022 |
| Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination JJ Garcés, M Simicek, M Vicari, L Brozova, L Burgos, R Bezdekova, ... Leukemia 34 (2), 589-603, 2020 | 50 | 2020 |
| Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia B Paiva, MB Vidriales, A Sempere, F Tarín, E Colado, C Benavente, ... Leukemia 35 (8), 2358-2370, 2021 | 33 | 2021 |
| Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma JJ Garcés, G Bretones, L Burgos, R Valdes-Mas, N Puig, MT Cedena, ... Leukemia 34 (11), 3007-3018, 2020 | 31 | 2020 |
| Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma S Rodriguez, J Celay, I Goicoechea, C Jimenez, C Botta, ... Science Advances 8 (3), eabl4644, 2022 | 24 | 2022 |
| More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma T Jelinek, R Bezdekova, D Zihala, T Sevcikova, AA Sithara, L Pospisilova, ... Journal of Clinical Oncology 41 (7), 1383, 2023 | 23 | 2023 |
| FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology C Botta, C Maia, JJ Garcés, R Termini, C Perez, I Manrique, L Burgos, ... Blood Advances 6 (2), 690-703, 2022 | 23 | 2022 |
| A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma C Guerrero, N Puig, MT Cedena, I Goicoechea, C Perez, JJ Garcés, ... Clinical Cancer Research 28 (12), 2598-2609, 2022 | 21 | 2022 |
| Immunologic characterization of COVID-19 patients with hematological cancer C Maia, E Martín-Sánchez, JJ Garcés, ALD De Cerio, S Inogés, ... Haematologica 106 (5), 1457, 2021 | 17 | 2021 |
| Immunological biomarkers of fatal COVID-19: a study of 868 patients E Martin-Sanchez, JJ Garces, C Maia, S Inoges, A Lopez-Diaz de Cerio, ... Frontiers in Immunology 12, 659018, 2021 | 16 | 2021 |
| Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma R Termini, D Žihala, E Terpos, A Perez-Montaña, T Jelínek, M Raab, ... Clinical Cancer Research 28 (21), 4771-4781, 2022 | 13 | 2022 |
| Biological characterization and clinical relevance of circulating tumor cells: opening the Pandora’s Box of multiple myeloma JJ Garcés, J San-Miguel, B Paiva Cancers 14 (6), 1430, 2022 | 11 | 2022 |
| Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): mechanism of egression, clinical significance and therapeutic endpoints JJ Garcés, N Puig, R Termini, MT Cedena, C Moreno, JJ Pérez, ... Blood 138, 76, 2021 | 7 | 2021 |
| Discordances between immunofixation (IFx) and minimal residual disease (MRD) assessment with next-generation flow (NGF) and sequencing (NGS) in patients (Pts) with multiple … S Rodríguez, I Goicoechea, K Gemenetzi, C Botta, A Agathangelidis, ... Blood 136, 5-6, 2020 | 6 | 2020 |
| Flowct: a semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets C Botta, C Maia, CP Ruiz, I Manrique, JJ Garcés, S Rodriguez, L Burgos, ... Blood 134, 4355, 2019 | 3 | 2019 |
| Non-invasive genetic profiling is highly applicable in multiple myeloma (MM) through characterization of circulating tumor cells (CTCs) L Burgos, D Alignani, JJ Garces, L Ortiz, T Jelinek, V Segura, L Sanoja, ... Blood 128 (22), 801, 2016 | 3 | 2016 |
| Waldenström’s macroglobulinemia (WM) is preceded by clonal lymphopoiesis including MYD88 L265P in progenitor B cells S Rodríguez, C Botta, J Celay, I Goicoechea, C Jiménez, ... Blood 136, 42-43, 2020 | 2 | 2020 |
| The pathogenesis of multiple myeloma (MM) is preceded by mutated lymphopoiesis and B cell oligoclonality that persist in patients with negative minimal residual disease (MRD) S Rodriguez, N Puig, K Gemenetzi, I Goicoechea, C Botta, ... Blood 134, 509, 2019 | 2 | 2019 |
